<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397239</url>
  </required_header>
  <id_info>
    <org_study_id>A-BR-103-062</org_study_id>
    <secondary_id>MOHW103-TD-B-111-06</secondary_id>
    <secondary_id>MOHW103-TDU-B-211-113002</secondary_id>
    <nct_id>NCT02397239</nct_id>
  </id_info>
  <brief_title>Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol title:&#xD;
&#xD;
      Comparison of cost-effectiveness of continuation maintenance therapy with six cycles of&#xD;
      pemetrexed versus pemetrexed until disease progression for metastatic non-squamous&#xD;
      non-small-cell lung cancer (NSCLC)&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      An open-labelled, randomized, phase 2 trial&#xD;
&#xD;
      Indication:&#xD;
&#xD;
      Patients with stage IV non-squamous NSCLC, an Eastern Cooperative Oncology Group (ECOG)&#xD;
      performance status of 0-1, and have received first-line or second-line chemotherapy with&#xD;
      pemetrexed plus platinum for 4 cycles&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles versus until disease&#xD;
      progression&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      1. Progression-free survival in the intention-to-treat population&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. Cost-effectiveness&#xD;
&#xD;
        2. Overall survival&#xD;
&#xD;
        3. Quality-of-life (QoL)&#xD;
&#xD;
        4. Quality-adjusted progression-free survival (QA-PFS)&#xD;
&#xD;
        5. Quality-adjusted life expectancy (QALE)&#xD;
&#xD;
        6. Tumor response rate&#xD;
&#xD;
        7. Adverse events&#xD;
&#xD;
      Planned sample size:&#xD;
&#xD;
      36 patients in each arm; total 72 patients&#xD;
&#xD;
      Total number of sites:&#xD;
&#xD;
      1 site&#xD;
&#xD;
      Duration of patient enrollment:&#xD;
&#xD;
      3 years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria:&#xD;
&#xD;
        1. Males and females ≥ 20 years of age&#xD;
&#xD;
        2. ECOG performance status of 0-1&#xD;
&#xD;
        3. Histologically or cytologically verified non-squamous NSCLC&#xD;
&#xD;
        4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging,&#xD;
           prior to first-line or second-line chemotherapy with pemetrexed plus platinum&#xD;
&#xD;
        5. At least one measurable lesion as defined by Response Evaluation Criteria in Solid&#xD;
           Tumors (RECIST) version 1.1&#xD;
&#xD;
        6. Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus&#xD;
           platinum and documented radiographic evidence of a complete or partial tumor response or&#xD;
           stable disease by RECIST 1.1&#xD;
&#xD;
        7. Adequate organ function, including followings:&#xD;
&#xD;
           Bone marrow:&#xD;
&#xD;
           Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet&#xD;
           count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
           Hepatic:&#xD;
&#xD;
           Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤ 3.0&#xD;
           x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL (≤&#xD;
           5.0 x UNL if liver metastasis)&#xD;
&#xD;
           Renal:&#xD;
&#xD;
           Estimated glomerular filtration rate ≥ 30 mL/min&#xD;
&#xD;
        8. Estimated life expectancy of at least 6 months&#xD;
&#xD;
        9. Ability to comply with study and follow-up procedures&#xD;
&#xD;
       10. Signed informed consent document&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. Squamous cell and/or mixed small-cell, non-small-cell histology&#xD;
&#xD;
        2. Prior participation in any investigational drug study within 4 weeks&#xD;
&#xD;
        3. Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years after&#xD;
           curative treatment, non-melanoma skin cancer or in situ cervical cancer&#xD;
&#xD;
        4. Serious concomitant systemic disorders, such as acute or recent myocardial infarction (&lt;&#xD;
           6 months before enrollment), congestive heart failure with New York Heart Association&#xD;
           functional class II~IV, frequent exacerbations of chronic obstructive pulmonary disease&#xD;
           (≥ 2 hospitalizations per year), or recent cerebrovascular disease (&lt; 6 months before&#xD;
           enrollment)&#xD;
&#xD;
        5. Active uncontrolled infections or HIV infection&#xD;
&#xD;
        6. Current or planned pregnancy, or breast feeding in women&#xD;
&#xD;
        7. Symptomatic central nervous system metastasis unless the patient has completed&#xD;
           successful local therapy and has been off corticosteroids for ≥ 4 weeks&#xD;
&#xD;
        8. Concurrent administration of any other antitumor therapy including chemotherapy, target&#xD;
           therapy, immunotherapy, and hormone therapy&#xD;
&#xD;
        9. Psychiatric disorders that would compromise the patient's compliance or decision&#xD;
&#xD;
      Criteria for evaluation:&#xD;
&#xD;
      QoL:&#xD;
&#xD;
      QoL will be measured using the EuroQol 5-dimensional questionnaire (EQ-5D), World Health&#xD;
      Organization Quality-of-Life, brief version (WHOQOL-BREF), European Organization for Research&#xD;
      and Treatment of Cancer (EORTC) questionnaires.&#xD;
&#xD;
      Efficacy:&#xD;
&#xD;
      Tumor response rate will be determined by RECIST 1.1. Data of progression-free survival and&#xD;
      overall survival will be collected for all subjects.&#xD;
&#xD;
      QA-PFS and QALE:&#xD;
&#xD;
      Investigators will adjust the progression-free survival by the utility values of QoL measured&#xD;
      from the EQ-5D to obtain the QA-PFS. In addition, investigators will extrapolate the survival&#xD;
      function to lifetime based on the survival ratios between patients and age- and sex-matched&#xD;
      referents simulated from the life tables of Taiwan. After adjusting the lifetime survival by&#xD;
      the utility values of QoL, the QALE will also be estimated using quality-adjusted life-year&#xD;
      (QALY) as the unit.&#xD;
&#xD;
      Cost-effectiveness:&#xD;
&#xD;
      The monthly healthcare expenditures, which included National Health Insurance-reimbursed and&#xD;
      out-of-pocket direct medical costs, will be obtained from the reimbursement database of&#xD;
      National Cheng Kung University Hospital. These values were multiplied by the corresponding&#xD;
      survival probabilities to calculate the lifetime costs or costs during the progression-free&#xD;
      period. Hence, costs/life-year or costs/QALY can be obtained for comparison of&#xD;
      cost-effectiveness.&#xD;
&#xD;
      Adverse events:&#xD;
&#xD;
      Safety parameters include laboratory adverse events (e.g., anemia, leukopenia, neutropenia,&#xD;
      thrombocytopenia, creatinine, AST, ALT) and non-laboratory adverse events (e.g., fatigue,&#xD;
      nausea, vomiting, mucositis/stomatitis, anorexia, diarrhea, constipation, infection, febrile&#xD;
      neutropenia, pain, sensory neuropathy, rash, edema, watery eye). Common Terminology Criteria&#xD;
      for Adverse Events (CTCAE) v4.0 will be used to grade toxicities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness: Cost/QA-PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Quality-adjusted progression-free survival (QA-PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life (QoL) Questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted progression-free survival (QA-PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-adjusted life expectancy (QALE)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Six cycles</arm_group_label>
    <description>Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Until disease progression</arm_group_label>
    <description>Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood hemoglobin, white blood cell, absolute neutrophil count, platelet count, total&#xD;
      bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic non-squamous mon-small-cell lung cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥ 20 years of age&#xD;
&#xD;
          2. ECOG performance status of 0-1&#xD;
&#xD;
          3. Histologically or cytologically verified non-squamous NSCLC&#xD;
&#xD;
          4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition&#xD;
             staging, prior to first-line or second-line chemotherapy with pemetrexed plus platinum&#xD;
&#xD;
          5. At least one measurable lesion as defined by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) version 1.1&#xD;
&#xD;
          6. Completion of 4 cycles of first-line or second-line chemotherapy with pemetrexed plus&#xD;
             platinum and documented radiographic evidence of a complete or partial tumor response&#xD;
             or stable disease by RECIST 1.1&#xD;
&#xD;
          7. Adequate organ function, including followings:&#xD;
&#xD;
             Bone marrow:&#xD;
&#xD;
             Absolute neutrophil count ≥ 1.5 x 103 /μL White blood cell ≥ 3.0 x 103 /μL Platelet&#xD;
             count ≥ 75 x 103 /μL Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
             Hepatic:&#xD;
&#xD;
             Total bilirubin ≤ 1.5 x upper normal limit (UNL) Aspartate aminotransferase (AST) ≤&#xD;
             3.0 x UNL (≤ 5.0 x UNL if liver metastasis) Alanine aminotransferase (ALT) ≤ 3.0 x UNL&#xD;
             (≤ 5.0 x UNL if liver metastasis)&#xD;
&#xD;
             Renal:&#xD;
&#xD;
             Estimated glomerular filtration rate ≥ 30 mL/min&#xD;
&#xD;
          8. Estimated life expectancy of at least 6 months&#xD;
&#xD;
          9. Ability to comply with study and follow-up procedures&#xD;
&#xD;
         10. Signed informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Squamous cell and/or mixed small-cell, non-small-cell histology&#xD;
&#xD;
          2. Prior participation in any investigational drug study within 4 weeks&#xD;
&#xD;
          3. Prior malignancy other than NSCLC, except those remain disease-free for ≥ 3 years&#xD;
             after curative treatment, non-melanoma skin cancer or in situ cervical cancer&#xD;
&#xD;
          4. Serious concomitant systemic disorders, such as acute or recent myocardial infarction&#xD;
             (&lt; 6 months before enrollment), congestive heart failure with New York Heart&#xD;
             Association functional class II~IV, frequent exacerbations of chronic obstructive&#xD;
             pulmonary disease (≥ 2 hospitalizations per year), or recent cerebrovascular disease&#xD;
             (&lt; 6 months before enrollment)&#xD;
&#xD;
          5. Active uncontrolled infections or HIV infection&#xD;
&#xD;
          6. Current or planned pregnancy, or breast feeding in women&#xD;
&#xD;
          7. Symptomatic central nervous system metastasis unless the patient has completed&#xD;
             successful local therapy and has been off corticosteroids for ≥ 4 weeks&#xD;
&#xD;
          8. Concurrent administration of any other antitumor therapy including chemotherapy,&#xD;
             target therapy, immunotherapy, and hormone therapy&#xD;
&#xD;
          9. Psychiatric disorders that would compromise the patient's compliance or decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Szu-Chun Yang, M.D.</last_name>
    <phone>+886-6-2353535</phone>
    <phone_ext>2595</phone_ext>
    <email>szuchunyang@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szu-Chun Yang, M.D.</last_name>
      <phone>+886 972402279</phone>
      <email>yangszuchun@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

